Wilhelmina Jenkins
Senior Member (Voting Rights)
I am so hoping that his successor knows anything at all about ME/CFS.
Notable that he is immediately stepping down and the US senate is currently going through... some things, let's say... and is unlikely to confirm a new NIH director for several weeks, if not months. I wonder what effect that will have given that the $1.15B funding seems to be entirely at the discretion of the director.
Does anyone have a handle on what is going on re: Collins? I was not sure what to make of this.
Ah, must have misread. I saw something that said tomorrow but was probably the official announcement then. Seeing his lack of interest while on the job, however, I can't imagine this transition period will change that positively given all the loose ends and singing goodbye and everything.He’s not stepping down immediately. It’s at the end of the year.
Medpage Today: Collins to Step Down as NIH Director at Year's End
We get mentioned:
Members of the myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) community panned the NIH and the research community in general for not taking the disease seriously enough, but Collins disagreed. "It's very hard for me to see how [that criticism is] fair when you hear stories of people who've gone rather suddenly from a full life to bedridden status -- something dramatic happened there," Collins said in 2018. The previous September, NIH had awarded $7 million in grants to three clinical centers and a data coordination center to continue ME/CFS research.
He added, however, that "there are problems [in that] CFS has become such a blurry diagnosis, that in there amongst hundreds of thousands or millions of people who carry that diagnosis is a whole heterogeneous group and there may be individuals ... who have something else entirely or even people who are suffering from depression and are therefore feeling fatigue for that [reason]. I think that's added to the difficulty that the medical care system has had coming to grips with this as a real disease that has a desperate need for new treatments."
You have to register to read it but it's not a paywall (the rest is not about ME/CFS): https://www.medpagetoday.com/publichealthpolicy/washington-watch/94861
He assigned Dr Nath, one of his best guys, to do the intramural study which, although it was cut short by the pandemic, has started to publish its findings
May I ask in what way was the intramural study cut short? Did it not look at all it said it would, or it studied less patients than originally planned? Thank you.
It’s in the budget currently being considered by Congress. I would imagine that a lot of Dr Collins’s remaining time will be spent pushing this forward. He is very good at obtaining funding from Congress.I was just reading on ARPA-H yesterday while I try to get up to speed on it.
When it says "under consideration" by US Congress, do we know what next steps are? How would this get passed?